文献速递卫生政策与健康促进

挪威医院庆大霉素与抗生素使用:2015至2023年35次点患病率调查

Gentamicin and antibiotic use in Norwegian hospitals: a study from 35 point-prevalence surveys, 2015 to 2023.
PubMed 文献 · Euro Surveill · 2026-01-01

该研究基于2015至2023年挪威68家医院35次全国点患病率调查,纳入≥20岁住院患者。241,546例中66,586例使用抗生素,年患病率26.9-28.1%。庆大霉素使用从2015年4.1%升至2023年5.8%,主要联用氨苄西林、青霉素或氨苄西林加甲硝唑;新冠疫情后此前上升趋势不再 observed。

要点

  • 挪威住院患者抗生素年患病率为26.9-28.1%,70-79岁组比例最高(26.4%)。
  • 庆大霉素使用从2015年4.1%升至2023年5.8%,主要联用氨苄西林、青霉素或氨苄西林加甲硝唑。
  • 新冠前庆大霉素使用呈上升趋势(β1: 0.105; p < 0.001),疫情后不再 observed(β3: -0.112; p = 0.013)。

核心结论

  • 挪威住院患者庆大霉素使用仍低但似高于其他欧洲国家,新冠后疫情前上升趋势不再 observed,支持监测和抗生素管理以减少广谱抗生素不必要使用。

研究设计与样本

  • 基于2015至2023年挪威68家医院35次全国点患病率调查,纳入≥20岁住院患者。

主要发现

  • 241,546例住院患者中66,586例使用抗生素,年患病率26.9-28.1%,70-79岁组26.4%、≥80岁组23.4%比例最高。
  • 氨基糖苷类(主要为庆大霉素)在所有抗生素处方中排第九位。
  • 自2021年起,第三代头孢菌素(13-14%)超过β-内酰胺酶敏感青霉素(12-13%)。
  • 庆大霉素使用从2015年4.1%升至2023年5.8%,主要联用氨苄西林、青霉素或氨苄西林加甲硝唑,主要适应证为尿路、下呼吸道、腹腔感染和脓毒症。
  • 新冠前庆大霉素使用上升趋势(β1: 0.105; p < 0.001)在2020年3月11日宣布全球大流行后不再 observed(β3: -0.112; p = 0.013)。

临床怎么用

  • 可利用全国点患病率调查监测庆大霉素使用趋势及联用模式,为抗生素管理提供依据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUNDInappropriate and excessive use of broad-spectrum antibiotics drives antimicrobial resistance. Gentamicin, an Access antibiotic in the WHO AWaRe framework with low resistance potential, has long been recommended in Norway for empirical treatment of serious infections. However, real-world data on aminoglycoside use remain limited.AIMWe aimed to describe gentamicin and overall antibiotic use in Norway, including COVID-19 pandemic-related changes, and report the extent of gentamicin use across selected indications.METHODSData were obtained from patients ≥ 20 years from 35 national point-prevalence surveys (2015-2023) across 68 Norwegian hospitals.RESULTSAmong 241,546 hospitalised patients, 66,586 received antibiotics (yearly prevalence 26.9-28.1%), with the highest proportions in the 70-79 (26.4%) and ≥ 80 (23.4%) years age groups. Aminoglycosides, mainly gentamicin, ranked ninth among all antibiotic prescriptions. From 2021, third-generation cephalosporins (13-14%) surpassed β-lactamase-sensitive penicillins (12-13%). Gentamicin use increased from 4.1% in 2015 to 5.8% in 2023, mainly in combination with ampicillin, benzylpenicillin, or ampicillin plus metronidazole. Main indications were urinary tract, lower respiratory tract and intraabdominal infections, and sepsis. An increasing pre-COVID-19 pandemic trend in gentamicin use (β1: 0.105; p < 0.001) was no longer observed after the COVID-19 outbreak was declared a global pandemic on the 11 March 2020 (β3: - 0.112; p = 0.013).CONCLUSIONGentamicin use among hospitalised patients in Norway remains low but appears higher than in other European countries. Increases in gentamicin use pre-COVID-19 pandemic were no longer observed after COVID-19, supporting the need for surveillance and antibiotic stewardship to minimise unnecessary use of broad-spectrum antibiotics.

来源:Euro Surveill,查看原文。版权归原作者所有。

引用

  1. Vuković M, Nordtveit S, Skodvin B, et al. Gentamicin and antibiotic use in Norwegian hospitals: a study from 35 point-prevalence surveys, 2015 to 2023. Euro Surveill. 2026. PMID: 42921685. doi:10.2807/1560-7917.ES.2026.31.42.2500969

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。